# Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia

> **NCT00539266** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Leiden University Medical Center** · enrollment: 108 (estimated)

## Conditions studied

- Intermittent Claudication
- Peripheral Vascular Diseases

## Interventions

- **BIOLOGICAL:** bone marrow derived mononuclear cells
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT00539266
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2011-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00539266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00539266, "Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00539266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*